A Phase II Study of Gemcitabine and Nanoparticle-Bound Paclitaxel as Second Line Therapy in Patients With Metastatic Pancreatic Cancer
Phase of Trial: Phase II
Latest Information Update: 16 Feb 2017
Price : $35 *
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 13 Feb 2017 Status changed from active, no longer recruiting to discontinued.
- 16 Feb 2016 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
- 24 Sep 2014 New trial record